

**Experiment Number:** C06100

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Perfluorohexane sulfonate potassium salt

**CAS Number:** 3871-99-6

**Date Report Requested:** 04/04/2018

**Time Report Requested:** 14:02:00

**Lab:** Battelle

**C Number:** C06100

**Cage Range:** All

**Date Range:** All

**Reasons For Removal:** All

**Removal Date Range:** All

**Treatment Groups:** All

**Study Gender:** Female

Experiment Number: C06100

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Perfluorohexane sulfonate potassium salt

CAS Number: 3871-99-6

Date Report Requested: 04/04/2018

Time Report Requested: 14:02:00

Lab: Battelle

Female

	Phase Day	Treatment Groups (mg/kg/day)														
		0		3.12		6.25		12.5		25						
Urea Nitrogen (mg/dL)	SD 28	19.5	± 0.8	(10)	17.9	± 0.3	(10)	19.3	± 0.6	(10)	18.9	± 0.4	(10)	19.0	± 0.5	(10)
Percent of Control					91.8			99.0			96.9			97.4		
Creatinine (mg/dL)	SD 28	0.75	± 0.02	(10)	0.76	± 0.02	(10)	0.73	± 0.02	(10)	0.74	± 0.02	(10)	0.75	± 0.02	(10)
Percent of Control					101.33			97.33			98.67			100.00		
Glucose (mg/dL)	SD 28	221.6	± 5.3	(10)	221.3	± 5.4	(10)	220.6	± 5.9	(10)	229.1	± 6.5	(10)	210.4	± 8.8	(10)
Percent of Control					99.9			99.5			103.4			94.9		
Total Protein (g/dL)	SD 28	6.33	± 0.05	(10)	6.27	± 0.06	(10)	6.23	± 0.05	(10)	6.42	± 0.07	(10)	6.38	± 0.07	(10)
Percent of Control					99.05			98.42			101.42			100.79		
Globulin (g/dL)	SD 28	1.90	± 0.03	(10)	1.88	± 0.06	(10)	1.85	± 0.05	(10)	1.91	± 0.07	(10)	1.82	± 0.06	(10)
Percent of Control					98.95			97.37			100.53			95.79		
A/G Ratio	SD 28	2.34	± 0.04	(10)	2.36	± 0.08	(10)	2.39	± 0.08	(10)	2.39	± 0.09	(10)	2.54	± 0.11	(10)
Percent of Control					100.83			102.21			102.14			108.63		
Albumin (g/dL)	SD 28	4.43	± 0.03	(10) **	4.39	± 0.04	(10)	4.38	± 0.03	(10)	4.51	± 0.04	(10)	4.56	± 0.05	(10)
Percent of Control					99.10			98.87			101.81			102.93		
Total Bilirubin (mg/dL)	SD 28	0.119	± 0.005	(10)	0.134	± 0.005	(10)	0.133	± 0.008	(10)	0.115	± 0.007	(10)	0.130	± 0.006	(10)
Percent of Control					112.637			112.047			97.051			109.351		
Direct Bilirubin (mg/dL)	SD 28	0.025	± 0.002	(10)	0.025	± 0.001	(10)	0.028	± 0.002	(10)	0.022	± 0.001	(10)	0.024	± 0.002	(10)
Percent of Control					97.638			109.843			88.189			93.307		
Indirect Bilirubin (mg/dL)	SD 28	0.093	± 0.005	(10)	0.109	± 0.005	(10)	0.105	± 0.007	(10)	0.093	± 0.007	(10)	0.106	± 0.007	(10)
Percent of Control					116.720			112.647			99.464			113.719		
Cholesterol (mg/dL)	SD 28	92.1	± 3.0	(10)	99.7	± 3.1	(10)	97.4	± 3.7	(10)	98.5	± 5.3	(10)	100.2	± 3.8	(10)
Percent of Control					108.3			105.8			106.9			108.8		

Experiment Number: C06100

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Perfluorohexane sulfonate potassium salt

CAS Number: 3871-99-6

Date Report Requested: 04/04/2018

Time Report Requested: 14:02:00

Lab: Battelle

Female

	Phase Day	Treatment Groups (mg/kg/day)																	
		0				3.12				6.25				12.5				25	
Triglyceride (mg/dL)	SD 28	68.4	± 4.7	(10)	86.9	± 7.9	(10)	77.3	± 7.9	(10)	69.2	± 5.8	(10)	75.0	± 8.0	(10)			
Percent of Control					127.0			113.0			101.2			109.6					
Alanine Aminotransferase (IU/L)	SD 28	43.40	± 2.34	(10)	46.50	± 1.34	(10)	46.00	± 2.07	(10)	44.80	± 3.23	(10)	46.00	± 2.31	(10)			
Percent of Control					107.14			105.99			103.23			105.99					
Alkaline Phosphatase (IU/L)	SD 28	145.2	± 6.2	(10)	139.8	± 5.9	(10)	148.5	± 10.6	(10)	138.3	± 6.9	(10)	159.5	± 7.0	(10)			
Percent of Control					96.3			102.3			95.2			109.8					
Aspartate Aminotransferase (U/L)	SD 28	59.50	± 1.55	(10)	58.10	± 1.65	(10)	58.70	± 1.02	(10)	63.80	± 3.57	(10)	61.30	± 1.35	(10)			
Percent of Control					97.65			98.66			107.23			103.03					
Creatine Kinase (IU/L)	SD 28	87.9	± 6.8	(10)	91.1	± 6.3	(10)	94.1	± 5.7	(10)	89.8	± 12.4	(10)	89.7	± 3.3	(10)			
Percent of Control					103.6			107.1			102.2			102.0					
Sorbitol Dehydrogenase (IU/L)	SD 28	7.0	± 0.8	(10)	6.5	± 0.5	(10)	6.4	± 0.5	(10)	6.2	± 1.0	(10)	7.0	± 0.3	(10)			
Percent of Control					92.9			91.4			88.6			100.0					
Bile salt/acids (umol/L)	SD 28	21.9	± 3.8	(10)	19.5	± 2.5	(10)	21.5	± 3.5	(10)	14.8	± 2.1	(10)	15.5	± 3.1	(10)			
Percent of Control					89.0			98.2			67.6			70.8					

**Experiment Number:** C06100

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Perfluorohexane sulfonate potassium salt

**CAS Number:** 3871-99-6

**Date Report Requested:** 04/04/2018

**Time Report Requested:** 14:02:00

**Lab:** Battelle

---

**Female**

---

		Treatment Groups	
	Phase Day	50	
Urea Nitrogen (mg/dL)	SD 28	20.5 ± 0.6	(10)
Percent of Control		105.1	
Creatinine (mg/dL)	SD 28	0.78 ± 0.02	(10)
Percent of Control		104.00	
Glucose (mg/dL)	SD 28	211.0 ± 8.2	(10)
Percent of Control		95.2	
Total Protein (g/dL)	SD 28	6.41 ± 0.08	(10)
Percent of Control		101.26	
Globulin (g/dL)	SD 28	1.85 ± 0.05	(10)
Percent of Control		97.37	
A/G Ratio	SD 28	2.48 ± 0.07	(10)
Percent of Control		106.04	
Albumin (g/dL)	SD 28	4.56 ± 0.06	(10)
Percent of Control		102.93	
Total Bilirubin (mg/dL)	SD 28	0.120 ± 0.008	(10)
Percent of Control		101.348	
Direct Bilirubin (mg/dL)	SD 28	0.024 ± 0.002	(10)
Percent of Control		94.882	
Indirect Bilirubin (mg/dL)	SD 28	0.096 ± 0.010	(10)
Percent of Control		103.108	
Cholesterol (mg/dL)	SD 28	96.1 ± 3.8	(10)
Percent of Control		104.3	

**Experiment Number:** C06100

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Perfluorohexane sulfonate potassium salt

**CAS Number:** 3871-99-6

**Date Report Requested:** 04/04/2018

**Time Report Requested:** 14:02:00

**Lab:** Battelle

---

**Female**

---

		Treatment Groups		
	Phase Day	50		
Triglyceride (mg/dL)	SD 28	82.7	± 5.7	(10)
Percent of Control		120.9		
Alanine Aminotransferase (IU/L)	SD 28	51.40	± 1.67	(10)
Percent of Control		118.43		
Alkaline Phosphatase (IU/L)	SD 28	147.0	± 7.0	(10)
Percent of Control		101.2		
Aspartate Aminotransferase (U/L)	SD 28	59.90	± 1.10	(10)
Percent of Control		100.67		
Creatine Kinase (IU/L)	SD 28	88.8	± 5.3	(10)
Percent of Control		101.0		
Sorbitol Dehydrogenase (IU/L)	SD 28	7.6	± 0.8	(10)
Percent of Control		108.6		
Bile salt/acids (umol/L)	SD 28	20.5	± 2.2	(10)
Percent of Control		93.6		

**Experiment Number:** C06100

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Perfluorohexane sulfonate potassium salt

**CAS Number:** 3871-99-6

**Date Report Requested:** 04/04/2018

**Time Report Requested:** 14:02:00

**Lab:** Battelle

LEGEND

---

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

Clinical Chemistry for gestation phase includes pregnant females only

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

Indirect Bilirubin calculated as Total Bilirubin - Direct Bilirubin.

**\*\* END OF REPORT \*\***